MedTrace Logo

Negative Hormone Receptor and APOcrine Lobular Invasive Breast Cancer

NCT07613151 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2026-05-29

No results posted yet for this study

Summary

The NAPOLI Study is a retrospective multicenter observational study designed to characterize negative hormone receptor and apocrine lobular invasive breast cancer. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.

Conditions

  • Lobular Breast Carcinoma

Interventions

PROCEDURE

Upfront Breast Surgery

Upfront Conservative or Demolitive Breast Surgery

RADIATION

Adjuvant Radiotherapy

Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery

DRUG

Endocrine Therapy

Adjuvant or Neoadjuvant Endocrine Therapy

DRUG

Chemotherapy

Adjuvant or Neoadjuvant Chemotherapy

Sponsors & Collaborators

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Principal Investigators

  • Francesco Milardi, MD · Veneto Institute of Oncology IRCCS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-05-01
Completion
2027-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07613151 on ClinicalTrials.gov